(MDT) Medtronic - Overview
Exchange: NYSE •
Country: Ireland •
Currency: USD •
Type: Common Stock •
ISIN: IE00BTN1Y115
Stock: Pacemaker, Valve, Pump, Monitor, Stapler
Total Rating 62
Risk 90
Buy Signal -0.33
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.12% |
| Yield on Cost 5y | 2.78% |
| Yield CAGR 5y | 3.46% |
| Payout Consistency | 97.7% |
| Payout Ratio | 50.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.7% |
| Relative Tail Risk | -5.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.67 |
| Alpha | 8.02 |
| Character TTM | |
|---|---|
| Beta | 0.429 |
| Beta Downside | 0.512 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.77% |
| CAGR/Max DD | 0.42 |
Description: MDT Medtronic January 27, 2026
Medtronic plc (NYSE:MDT) designs, manufactures, and markets a broad range of device-based therapies across five main portfolios: Cardiovascular, Neuroscience, Medical Surgical, Diabetes, and a growing suite of digital health solutions. Its products span implantable cardiac devices, aortic and transcatheter valves, spinal and brain stimulation systems, robotic-assisted surgical tools, insulin pumps, and continuous glucose monitors, serving hospitals, physicians, and patients worldwide, with the United States accounting for roughly 60% of total sales.
Key recent metrics: FY 2023 revenue reached $31.7 billion, up 2% YoY, with the Cardiovascular segment contributing about 45% of that total; Q1 2024 reported revenue of $8.2 billion, maintaining an operating margin near 27%; R&D spending was $2.2 billion, reflecting a 9% increase year-over-year to sustain pipeline growth. The broader medical-device sector is projected to expand at a CAGR of ~6% through 2028, driven by an aging global population, rising chronic disease prevalence, and accelerating adoption of remote-monitoring technologies.
For a deeper quantitative assessment, you may find the ValueRay platform’s detailed valuation models useful.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 4.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.41 > 1.0 |
| NWC/Revenue: 40.45% < 20% (prev 31.04%; Δ 9.41% < -1%) |
| CFO/TA 0.08 > 3% & CFO 7.11b > Net Income 4.76b |
| Net Debt (27.82b) to EBITDA (9.27b): 3.00 < 3 |
| Current Ratio: 2.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago 0.05% < -2% |
| Gross Margin: 62.27% > 18% (prev 0.65%; Δ 6162 % > 0.5%) |
| Asset Turnover: 38.32% > 50% (prev 36.65%; Δ 1.68% > 0%) |
| Interest Coverage Ratio: 9.03 > 6 (EBITDA TTM 9.27b / Interest Expense TTM 710.0m) |
Altman Z'' 3.32
| A: 0.15 (Total Current Assets 24.00b - Total Current Liabilities 9.94b) / Total Assets 91.35b |
| B: 0.35 (Retained Earnings 32.07b / Total Assets 91.35b) |
| C: 0.07 (EBIT TTM 6.41b / Avg Total Assets 90.69b) |
| D: 0.65 (Book Value of Equity 27.80b / Total Liabilities 42.49b) |
| Altman-Z'' Score: 3.32 = A |
Beneish M -3.02
| DSRI: 0.97 (Receivables 6.39b/6.26b, Revenue 34.76b/33.00b) |
| GMI: 1.04 (GM 62.27% / 65.05%) |
| AQI: 0.97 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 1.05 (Revenue 34.76b / 33.00b) |
| TATA: -0.03 (NI 4.76b - CFO 7.11b) / TA 91.35b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of MDT shares?
As of February 04, 2026, the stock is trading at USD 103.18 with a total of 10,725,590 shares traded.
Over the past week, the price has changed by +2.47%, over one month by +5.98%, over three months by +15.23% and over the past year by +17.57%.
Over the past week, the price has changed by +2.47%, over one month by +5.98%, over three months by +15.23% and over the past year by +17.57%.
Is MDT a buy, sell or hold?
Medtronic has received a consensus analysts rating of 3.81.
Therefore, it is recommended to buy MDT.
- StrongBuy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the MDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.2 | 6.8% |
| Analysts Target Price | 110.2 | 6.8% |
| ValueRay Target Price | 107.1 | 3.8% |
MDT Fundamental Data Overview January 31, 2026
P/E Trailing = 27.3713
P/E Forward = 16.6667
P/S = 3.727
P/B = 2.6614
P/EG = 3.5613
Revenue TTM = 34.76b USD
EBIT TTM = 6.41b USD
EBITDA TTM = 9.27b USD
Long Term Debt = 27.62b USD (from longTermDebt, last quarter)
Short Term Debt = 1.42b USD (from shortTermDebt, last quarter)
Debt = 29.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 27.82b USD (from netDebt column, last quarter)
Enterprise Value = 157.36b USD (129.54b + Debt 29.10b - CCE 1.28b)
Interest Coverage Ratio = 9.03 (Ebit TTM 6.41b / Interest Expense TTM 710.0m)
EV/FCF = 30.23x (Enterprise Value 157.36b / FCF TTM 5.21b)
FCF Yield = 3.31% (FCF TTM 5.21b / Enterprise Value 157.36b)
FCF Margin = 14.98% (FCF TTM 5.21b / Revenue TTM 34.76b)
Net Margin = 13.71% (Net Income TTM 4.76b / Revenue TTM 34.76b)
Gross Margin = 62.27% ((Revenue TTM 34.76b - Cost of Revenue TTM 13.11b) / Revenue TTM)
Gross Margin QoQ = 60.32% (prev 57.66%)
Tobins Q-Ratio = 1.72 (Enterprise Value 157.36b / Total Assets 91.35b)
Interest Expense / Debt = 0.62% (Interest Expense 181.0m / Debt 29.10b)
Taxrate = 13.47% (215.0m / 1.60b)
NOPAT = 5.54b (EBIT 6.41b * (1 - 13.47%))
Current Ratio = 2.42 (Total Current Assets 24.00b / Total Current Liabilities 9.94b)
Debt / Equity = 0.60 (Debt 29.10b / totalStockholderEquity, last quarter 48.65b)
Debt / EBITDA = 3.00 (Net Debt 27.82b / EBITDA 9.27b)
Debt / FCF = 5.34 (Net Debt 27.82b / FCF TTM 5.21b)
Total Stockholder Equity = 48.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.25% (Net Income 4.76b / Total Assets 91.35b)
RoE = 9.83% (Net Income TTM 4.76b / Total Stockholder Equity 48.49b)
RoCE = 8.42% (EBIT 6.41b / Capital Employed (Equity 48.49b + L.T.Debt 27.62b))
RoIC = 7.23% (NOPAT 5.54b / Invested Capital 76.64b)
WACC = 6.22% (E(129.54b)/V(158.64b) * Re(7.50%) + D(29.10b)/V(158.64b) * Rd(0.62%) * (1-Tc(0.13)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.68%
[DCF Debug] Terminal Value 85.18% ; FCFF base≈5.32b ; Y1≈5.41b ; Y5≈5.92b
Fair Price DCF = 102.4 (EV 159.10b - Net Debt 27.82b = Equity 131.29b / Shares 1.28b; r=6.22% [WACC]; 5y FCF grow 1.39% → 2.90% )
EPS Correlation: 12.99 | EPS CAGR: -0.20% | SUE: 2.62 | # QB: 4
Revenue Correlation: 76.34 | Revenue CAGR: 3.90% | SUE: 1.26 | # QB: 2
EPS current Year (2026-04-30): EPS=5.66 | Chg30d=+0.002 | Revisions Net=-2 | Growth EPS=+3.0% | Growth Revenue=+7.5%
EPS next Year (2027-04-30): EPS=6.12 | Chg30d=-0.000 | Revisions Net=-1 | Growth EPS=+8.1% | Growth Revenue=+5.7%
P/E Forward = 16.6667
P/S = 3.727
P/B = 2.6614
P/EG = 3.5613
Revenue TTM = 34.76b USD
EBIT TTM = 6.41b USD
EBITDA TTM = 9.27b USD
Long Term Debt = 27.62b USD (from longTermDebt, last quarter)
Short Term Debt = 1.42b USD (from shortTermDebt, last quarter)
Debt = 29.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 27.82b USD (from netDebt column, last quarter)
Enterprise Value = 157.36b USD (129.54b + Debt 29.10b - CCE 1.28b)
Interest Coverage Ratio = 9.03 (Ebit TTM 6.41b / Interest Expense TTM 710.0m)
EV/FCF = 30.23x (Enterprise Value 157.36b / FCF TTM 5.21b)
FCF Yield = 3.31% (FCF TTM 5.21b / Enterprise Value 157.36b)
FCF Margin = 14.98% (FCF TTM 5.21b / Revenue TTM 34.76b)
Net Margin = 13.71% (Net Income TTM 4.76b / Revenue TTM 34.76b)
Gross Margin = 62.27% ((Revenue TTM 34.76b - Cost of Revenue TTM 13.11b) / Revenue TTM)
Gross Margin QoQ = 60.32% (prev 57.66%)
Tobins Q-Ratio = 1.72 (Enterprise Value 157.36b / Total Assets 91.35b)
Interest Expense / Debt = 0.62% (Interest Expense 181.0m / Debt 29.10b)
Taxrate = 13.47% (215.0m / 1.60b)
NOPAT = 5.54b (EBIT 6.41b * (1 - 13.47%))
Current Ratio = 2.42 (Total Current Assets 24.00b / Total Current Liabilities 9.94b)
Debt / Equity = 0.60 (Debt 29.10b / totalStockholderEquity, last quarter 48.65b)
Debt / EBITDA = 3.00 (Net Debt 27.82b / EBITDA 9.27b)
Debt / FCF = 5.34 (Net Debt 27.82b / FCF TTM 5.21b)
Total Stockholder Equity = 48.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.25% (Net Income 4.76b / Total Assets 91.35b)
RoE = 9.83% (Net Income TTM 4.76b / Total Stockholder Equity 48.49b)
RoCE = 8.42% (EBIT 6.41b / Capital Employed (Equity 48.49b + L.T.Debt 27.62b))
RoIC = 7.23% (NOPAT 5.54b / Invested Capital 76.64b)
WACC = 6.22% (E(129.54b)/V(158.64b) * Re(7.50%) + D(29.10b)/V(158.64b) * Rd(0.62%) * (1-Tc(0.13)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.68%
[DCF Debug] Terminal Value 85.18% ; FCFF base≈5.32b ; Y1≈5.41b ; Y5≈5.92b
Fair Price DCF = 102.4 (EV 159.10b - Net Debt 27.82b = Equity 131.29b / Shares 1.28b; r=6.22% [WACC]; 5y FCF grow 1.39% → 2.90% )
EPS Correlation: 12.99 | EPS CAGR: -0.20% | SUE: 2.62 | # QB: 4
Revenue Correlation: 76.34 | Revenue CAGR: 3.90% | SUE: 1.26 | # QB: 2
EPS current Year (2026-04-30): EPS=5.66 | Chg30d=+0.002 | Revisions Net=-2 | Growth EPS=+3.0% | Growth Revenue=+7.5%
EPS next Year (2027-04-30): EPS=6.12 | Chg30d=-0.000 | Revisions Net=-1 | Growth EPS=+8.1% | Growth Revenue=+5.7%